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Abstract
Background—We investigated 12 variables and their interactions as correlates of smoking
cessation among regular smokers in the population-based Swedish Twin Registry (STR).
Method—Detailed information on tobacco use and personal characteristics were available from
14 715 male and female twins aged 42–64 years who participated in a screening of the population-
based STR and reported being regular smokers in their lifetime. A two-stage analytic design was
used to examine correlates of smoking cessation. The sample was split at random and significant
main effects and interactions identified in the testing set were examined in the validation set.
Hazard ratios (HRs) and 95% confidence intervals (CIs) describe the association between
correlates and smoking cessation.
Results—Twelve main effects were significantly associated with smoking cessation in the
testing set; eight were confirmed in the validation set. Of the nine interactions identified in the
testing set, none remained significant when evaluated in the validation set after Bonferroni
correction. HRs were highest for Swedish oral smokeless tobacco (snus) use (HR 2.70, 95% CI
2.30–3.20), >11 years of education (HR 1.57, 95% CI 1.43–1.73) and being married or
cohabitating (HR 1.51, 95% CI 1.39–1.63). Although not statistically significant after Bonferroni
correction, snus use also appeared important in the context of interactions, where lower nicotine
dependence score, higher socio-economic status (SES) and greater body size were associated with
smoking cessation only among participants who never used snus.
Conclusions—Snus use was the strongest independent correlate of smoking cessation. Further
studies should investigate the mechanism of this association.
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To reduce the impact of tobacco use on health worldwide, tobacco users have been urged to
quit for decades. Although the majority of smokers are aware of deleterious health effects of
smoking, and over 46% make an active attempt to quit each year, only 2.3% achieve
sustained abstinence (Silagy et al. 2004). An improved understanding of the factors, or
combinations of factors, associated with smoking cessation is needed to develop more
effective intervention strategies to achieve maximum reductions in death and disease from
tobacco use.
A substantial amount of research has consistently identified individual factors associated
with smoking cessation using different study designs in various populations, such as male
gender, higher education and lower nicotine dependence score (Hyland et al. 2004). A
tobacco-related variable that has received recent attention as a potential harm reduction
product is Swedish snus, a moist smokeless tobacco product that contains lower
concentrations of cancer-causing tobacco-specific nitrosamines than found in other
smokeless tobacco products and cigarettes (Curvall et al. 1987; Foulds et al. 2003; Osterdahl
et al. 2004). Snus appears to be important in decreasing the prevalence of cigarette smoking
in Sweden (Ramstrom, 2000, 2003a, b; Rodu et al. 2002, 2003; Foulds et al. 2003; Gilljam &
Galanti, 2003; Furberg et al. 2005, 2006; Stegmayr et al. 2005; Ramstrom & Foulds, 2006),
as it delivers similar levels of nicotine as cigarettes but carries substantially lower risks of
cancer than cigarettes (Lewin et al. 1998; Schildt et al. 1998; Ye et al. 1999; Lagergren et
al. 2000; Accortt et al. 2002; Rodu & Jansson, 2004; Luo et al. 2007). Snus is available in
Sweden and Norway but it is banned in the rest of the European Union. The recent
introduction of Swedish snus into the American market by RJ Reynolds and Phillip Morris
has forced the debate over the potential of snus as a harm-reduction product from the
tobacco control community (Fagerstrom & Schildt, 2003; Gilljam & Galanti, 2003) to the
international health community (Lambe, 2004, 2007; Gray, 2005; Savitz et al. 2006; Foulds
& Kozlowski, 2007; Gartner et al. 2007; McKee & Gilmore, 2007).
Only one study has evaluated Swedish snus together with other characteristics as a potential
predictor of smoking cessation (Lindstrom & Isacsson, 2002), and this study requires
replication. Other prior studies on predictors of smoking cessation are problematic because
of the small, clinically based samples of participants, a focus on a limited set of individual
variables, and the omission of a test of interactions between variables. Failure to examine
interactions between factors disguises potentially important associations and may yield a
distorted picture of smoking cessation. In the study presented here, we rigorously
investigated the correlates of smoking cessation by evaluating 12 variables and their 66 two-
way interactions in a large, population-based sample of male and female regular smokers in
Sweden (n=14 715).
Method
Swedish Twin Registry (STR)
The STR is the largest population-based registry of twin births in the world (Lichtenstein et
al. 2002; Pedersen et al. 2002). The STR contains data on current vital status, marital status,
address, and place of birth for >99% of all ~170 000 Swedish twins (ages 0–103 years). The
data collection procedures were reviewed and approved by the Regional Ethics Committee
of the Karolinska Institutet. All subjects provided verbal informed consent during the
telephone interview, which was later confirmed by postcard.
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Assessment of smoking cessation
Over a 4-year period ending in December 2002, all living, contactable, interviewable, and
consenting twins in the STR born 1 January 1935 to 31 December 1958 were screened for a
range of disorders that included tobacco use (Lichtenstein et al. 2006). Detailed tobacco use
information from a telephone interview was available on 31 213 participants aged 42–64
years. Less than 1% of the twins interviewed did not contribute tobacco use information
(n=212, 0.7%) and they were more likely to be male and older (mean and standard deviation
of age of those lacking tobacco use information 55.9±5.7 v. 53.7±5.8, p<0.001). Participants
answered questions regarding the types of tobacco they used during their lifetime (cigarettes
and/or snus), age of initiation for each type of tobacco use, and whether they used tobacco at
interview. In addition, participants provided information on the type of cigarette user they
considered themselves to be; they could describe themselves either as a regular smoker,
someone who smokes now and then, someone who smokes at parties, or someone who has
never even tried cigarettes.
Our analytic interest in this report was to determine robust correlates of smoking cessation,
which necessitated restricting analyses to participants who reported having ever been a
regular smoker (n=15 956, 51.1%). The outcome measure in this analysis was smoking
cessation, and we compared former to current smokers. Lifetime regular smokers who did
not use cigarettes in the past month were considered former smokers; all other regular
smokers were classified as current smokers.
Candidate independent variables
We examined 12 dichotomous variables from three domains as possible correlates of
smoking cessation. Sociodemographic factors included sex (male versus female), marital
status (married or cohabitating versus divorced, separated or widowed), education level (>11
years versus ≤11 years) and socio-economic status (SES; white-collar versus blue-collar
SES). SES was assessed using the Swedish socio-economic classification of occupational
categories (Statistics Sweden, 1983). Occupations requiring manual labor, such as
construction workers, were grouped into blue-collar SES, whereas non-manual workers,
such as office managers, were considered white-collar SES (Novak et al. 2006).
Tobacco use variables included the age each participant began smoking cigarettes
(dichotomized at median; >16 years versus ≤16 years), whether they ever used snus in their
lifetime (yes versus no), and their Fagerstrom Test of Nicotine Dependence (FTND) score at
the time in their lives of maximum cigarette use (FTND score ≤5 versus >5) (Fagerstrom &
Schneider, 1989; Heatherton et al. 1991; Radzius et al. 2003). FTND score was
dichotomized based on prior literature where higher FTND score reflects greater nicotine
dependence (Breslau & Johnson, 2000; Breslau et al. 2001).
Medical history variables of relevance to smoking cessation included self-reported lifetime
history of alcohol abuse or dependence (APA, 1994), lifetime history of major depression
(APA, 1994), and lifetime history of significant airway disease (SAD) (all yes versus no).
Participants who reported a lifetime history of asthma, chronic bronchitis or emphysema
were classified as having SAD. In addition, current body mass index (BMI) was calculated
from self-reported height and weight at the time of interview and categorized into
overweight (25–30 kg/m2) or obese (>30 kg/m2) versus non-overweight (<25 kg/m2)
(WHO, 1998). Finally, participants reported their current self-perceived health status by
answering, ‘Do you think that your health status prevents you from doing things that you
want to do?’ (no versus yes).
To be included in these analyses, all regular smokers had to have contributed a non-missing
value for all independent variables. Of the 15 956 regular smokers, 1241 (7.7%) participants
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had at least one missing value for any independent variable and were excluded from the
analyses. The final sample size of this analysis was n=14 715. Compared to participants
included in the analyses, participants excluded from the analyses were more likely to be
former smokers, unmarried, have <11 years of education, be classified as blue-collar SES,
and report a later age at onset of cigarette smoking (p<0.01). We speculate on the impact of
these exclusions on the generalizability of our findings in the Discussion.
Statistical analyses
Analyses were conducted with SAS version 9.1.3 (SAS Institute, 2004). Because of the large
number of main effects and two-way interactions, we used a two-stage analytic design to
help ensure that factors and interactions confirmed as significant correlates were not
unreliable estimates due to the initial association overestimating the true effect size (Harrell
et al. 1985, 1996; Hastie et al. 2001). We randomly assigned regular smokers from the STR
(n=14 715) into two groups: the test set (n=7357) and the validation set (n=7358). As
expected, slight differences in proportions of variables were observed between the test and
validation sets because we divided the sample at random. To verify that the randomization
was successful, we confirmed that all associations between the independent variables and set
status were not significant (all p>0.15; data not shown).
First, in the test set, we evaluated the associations between smoking cessation and 12
independent variables and all 66 two-way interactions between these variables. Cox
proportional hazards (CPH) models (Cox & Oakes, 1984) accounted for the length of time
an individual had been a smoker and produced hazard ratios (HRs) and 95% confidence
intervals (CIs) that describe the hazard that an individual is a former smoker versus current
smoker at the time of interview (Allison, 1995). Models containing all main effects and
interactions were evaluated using stepwise selection (Shtatland et al. 2001).
Second, in the validation set, we attempted to verify which of the associations from the
testing set could be confirmed in the second half of the sample. Variables identified as
significant main effects or interactions (p<0.05) in the testing set were examined in the
validation set using a CPH model with no model selection. In the validation set, we applied
a Bonferroni correction to account for multiple testing (Bonferroni, 1936). To meet criteria
for statistical significance in the validation set, the α level was 0.0006 [0.05 divided by 78
tests (12 main effects and 66 interactions)]. Interactions were interpreted in terms of a
departure from the multiplicative scale (Rothman & Greenland, 1998).
Addressing the twin structure of the data
In the test set, there were 937 complete twin pair sets (n=1874; 25.5%), and in the validation
set there were 864 complete twin pair sets (n=1728, 23.5%). As twin pairs may contribute
correlated data that can influence the standard errors of the parameter estimates (Liang &
Zeger, 1986), we dropped one twin from each pair at random from each set and reran the
analyses. Excluding these individuals did not substantially alter the results. The same main
effects and interactions were confirmed as significant in the validation set. The only
consistent difference we observed between the results was the wider CIs of the non-twin
subset, probably due to the diminished sample size. Therefore, the findings presented in this
paper were derived from the complete dataset containing all twins.
Results
Description of study sample and creation of test and validation sets
Of the entire sample screened (n=31 213), about half reported having smoked regularly at
some point in their lives (n=15 947, 51.1%). The second column of Table 1 presents the
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distributions of participant characteristics of lifetime regular smokers included in this
analysis (after excluding subjects with missing data, n=14 715, 47.1%). Fifty-six per cent of
the regular smokers were former smokers and 44.0% were current smokers at the time of
interview.
In the first part of our two-stage analytic design, we randomly split the sample of lifetime
regular smokers into a test set (n=7357) and a validation set (n=7358). Table 1 also stratifies
the test and validation sets by former and current smoking status. Inspection of these
proportions shows that there were profound differences between former and current smokers
(e.g. male sex or snus use). Moreover, these differences are similar between the test and
validation sets. The mean total number of years smoked was ~19 years for former smokers
and ~35 years for current smokers in both sets, underscoring the need to use HRs in our
analytic approach.
Screening correlates of smoking cessation in the test set
Within the test set, we evaluated the statistical significance of 12 independent variables and
all 66 two-way interactions in relation to smoking cessation (α<0.05). Table 2 presents the
adjusted HRs and 95% CIs of smoking cessation from each set. In the test set, all of the
variables were significantly associated with smoking cessation as main effects. Of the 66
interaction terms examined in relation to smoking cessation in the test set, nine interactions
were found to be statistically significant (data not shown).
Confirmation of correlates of smoking cessation in the validation set
In the second part of our two-stage analytic design, all variables that were significant main
effects or interactions in the test set were re-examined in the validation set (Table 2). Of the
12 main effects identified as significant correlates of smoking cessation in the test set, eight
were confirmed as significant correlates of smoking cessation in the validation set after
Bonferroni correction for multiple comparisons (p<0.0006). In the validation set, a lifetime
history of snus use exhibited the highest HR for smoking cessation. Participants who had
ever used snus were nearly three times as likely to be former smokers than those who had
never used snus (HR 2.7, 95% CI 2.30–3.20). Other factors significantly associated with
smoking cessation included being married/cohabitating, higher education, white-collar SES,
later age at onset of smoking, lower FTND score, no lifetime history of alcohol abuse or
dependence, and higher BMI.
Interactions with snus use—Of the nine interactions identified as significant in the test
set, none were regarded as statistically significant after Bonferroni correction in the
validation set (all p<0.0006; data not shown). However, as this is the only study, to our
knowledge, that has examined interactions between variables with respect to smoking
cessation, we interpreted several interactions as suggestive. Three of the four suggestive
interactions involved snus use. A lifetime history of snus use modified the associations
between smoking cessation and FTND score, SES and BMI. Among people who had never
used snus, lower FTND score, white-collar SES and higher BMI remained significant
correlates of smoking cessation. However, among people who had used snus, the HRs for
these variables and smoking cessation were attenuated, suggesting that these factors are not
associated with smoking cessation among snus users.
Interaction with sex—The association between education and smoking cessation differed
slightly between women and men. Higher education level was more strongly associated with
smoking cessation among women (HR 1.58, 95% CI 1.43–1.75) than men (HR 1.23, 95% CI
1.11–1.35).
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Based on the magnitude of the HRs, lifetime history of snus use was the strongest individual
correlate of smoking cessation. Although not statistically significant after Bonferroni
correction, several suggestive interactions were observed. Snus use appeared to modify
associations between several variables and smoking cessation, such that lower FTND score,
white-collar SES and higher BMI were only associated with smoking cessation among
people who had never used snus. A higher proportion of men than women were former
smokers, but sex was not confirmed as a significant independent correlate of smoking
cessation in this analysis. Instead, sex modified the association between smoking cessation
and education.
Disentangling the effects of snus on smoking cessation
Only one previous study has evaluated the impact of Swedish snus together with other
participant characteristics as predictors of smoking cessation, and their findings are
consistent with this report. Lindstrom & Isacsson (2002) examined predictors of smoking
cessation in a longitudinal study of daily smokers aged 45–69 years in Sweden and found
that baseline daily smokers who became intermittent smokers at 1-year follow-up reported
higher snus consumption, particularly among men.
Snus use modified the associations between smoking cessation and three variables: FTND
score, SES and BMI. Lower nicotine dependence, higher SES and higher BMI have been
consistently associated with a greater likelihood of cessation in previous studies (Kaprio &
Koskenvuo, 1988; Osler et al. 1999; Fernandez et al. 2001; Broms et al. 2004; Hyland et al.
2004; Janzon et al. 2005; van Loon et al. 2005). We observed these patterns only among
people who had never used snus. Among those who had used snus, the effects of these
factors were diminished or eliminated, suggesting that the effects of these factors on
smoking cessation were less important in the presence of snus use.
It is reasonable to speculate that FTND score was a less important correlate of smoking
cessation among snus users because snus contains similar levels of nicotine as cigarettes
(Holm et al. 1992; Lunell & Lunell, 2005), perhaps helping all people quit smoking
regardless of their physiological dependence on cigarettes. It is possible that white-collar
SES was not a significant correlate of smoking cessation among snus users because snus is
widely available in Sweden and relatively inexpensive. In our sample, the proportion of ever
lifetime snus use among participants classified as white-collar or blue-collar SES was
similar (50.2% and 49.8% respectively).
The finding that higher BMI was not associated with smoking cessation among people who
used snus deserves further attention. Our data are cross-sectional and we did not have
information about the timing of weight gain or body size in relation to smoking cessation.
However, it is possible that higher BMI was not associated with smoking cessation among
snus users because the nicotine in snus could inhibit weight gain through appetite
suppression or an increase in metabolism (Audrain et al. 1995; Li et al. 2003). Consistent
with this hypothesis, Rodu et al. (2004) reported that although cessation of either cigarettes
or snus led to increased weight gain in Swedish males, smokers who switched to snus gained
significantly less weight.
Swedes appear to be using snus as a form of nicotine replacement therapy (NRT) despite a
lack of clinical trials data to support its use as a smoking cessation aid. Ramström & Foulds
(2006) reported that, among Swedish men trying to quit smoking, 24% of them used snus on
their latest quit attempt. They also found that both men and women using snus as a cessation
aid were significantly more likely to quit smoking successfully than those using nicotine
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patches or nicotine gum. These estimates are similar to another Swedish study that found
29% of male former smokers had used snus to quit smoking (Gilljam & Galanti, 2003).
Formal clinical trials are needed to test and compare the efficacy and side-effects of Swedish
snus with existing NRT products. In the USA, the Food and Drug Administration (FDA) has
approved five NRT products (transdermal patch, chewing gum, nasal spray, lozenge and
inhaler) and two non-nicotine pharmacotherapies (burpropion and varenicline) for the
treatment of nicotine dependence (Foulds et al. 2006; Schnoll & Lerman, 2006). Approved
NRT products are generally equally effective in aiding long-term cessation, roughly
doubling the odds of quitting as compared with placebo (Silagy et al. 2004). However, even
with effective NRTs, only one-quarter to one-third of smokers are able to quit smoking in
the long term (Silagy et al. 2004). Snus may be an effective NRT product because it delivers
approximately double the nicotine dose contained in approved NRT products, a level
comparable to that obtained by cigarettes (Holm et al. 1992; Lunell & Lunell, 2005).
Furthermore, unlike approved NRT products that are intended for short-term use, snus is
often used long term (Ramstrom & Foulds, 2006).
Data on the health consequences of long-term snus use at the individual level and population
level are accumulating. Among Swedish males followed up for 20 years, snus use was
associated with increased pancreatic cancer, but not with oral or lung cancer (Luo et al.
2007). The high levels of nicotine in snus may contribute to the increased risks in metabolic
syndrome (Norberg et al. 2006) and type II diabetes (Persson et al. 2000), but not all studies
support this hypothesis (Eliasson et al. 2004). Data on the risk of circulatory disease,
including cardiovascular disease and stroke, with snus use are conflicting (Huhtasaari et al.
1992, 1999; Bolinder et al. 1994; Asplund, 2003; Asplund et al. 2003; Hergens et al. 2005;
Johansson et al. 2005; Haglund et al. 2007; Lee, 2007). As nicotine is a neuroteratogen,
nicotine-containing products, including snus, should be avoided during pregnancy (Ginzel et
al. 2007).
At the population level, Gartner et al. (2007) assessed the potential population health effects
of Swedish snus across different patterns of use in Australia and found a net benefit to health
if adult smokers switched to snus. Similarly, in an assessment of a potential harm reduction
policy by introducing low-nitrosamine smokeless tobacco (such as Swedish snus) under
strict regulations in the USA, Levy et al. (2006) reported that it would probably yield
substantial health benefits.
Disentangling the effects of sex on smoking cessation
Consistent with previous research, a higher proportion of men than women were former
smokers in our study (Hyland et al. 2004). However, this difference became non-significant
in the adjusted analysis. Instead, sex was a potential modifier of the association between
education and smoking cessation. Higher education was a stronger correlate of smoking
cessation among women than men in our study. The suggestive interaction that we observed
between sex and education on smoking cessation has been reported previously by Osler et
al. (1999), who speculated that poorly educated women may continue smoking because of
the stress from additional caring responsibilities and restricted access to material resources.
Another possible explanation of our finding is that women are more accurate at
acknowledging health risks than men; this may be particularly true for highly educated
women (Perrin et al. 2005).
Study limitations and strengths
We acknowledge the cross-sectional design of this study and assert that the associations
observed are not necessarily causal. For several of the medical history variables, temporality
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was not clear; we did not know whether the medical condition prompted the participant to
quit smoking or vice versa. This may explain why we did not observe strong associations
between some of these variables and smoking cessation (e.g. history of SAD).
Selection bias may have threatened the validity of our results, and nearly 8% of the regular
smokers were excluded from the analysis as they contributed a missing value on any of the
potential correlates of smoking cessation. To address this issue, we examined associations
between correlates of smoking cessation among those excluded from the analysis because
they had partial data. Patterns among those excluded were identical to those in this report
(data not shown), thereby alleviating our concern of selection bias.
The strengths of this study include its population-based design, the detailed assessment of
cigarette and snus use, the diverse set of variables that were evaluated as correlates of
smoking cessation as main effects and interactions and, most notably, the efficient two-stage
analysis design within a large sample that enabled us to validate factors associated with
smoking cessation in one data source. There is compelling evidence that data from twin
registries are generalizable to the population at large and are a sound resource for
epidemiologic investigations, despite twins having higher morbidity and mortality during the
first year of life than singletons and comprising only 1–2% of the adult population
(Lichtenstein et al. 2002). Evans & Martin (2000) concluded that twins are representative of
the general population with respect to most health and behavioral outcomes because twins
exhibit similar means, frequencies and prevalences as singeltons for many traits and adult
diseases.
Research ethics
Presenting these data for publication poses an ethical dilemma for a biomedical researcher
mindful of the business practices used by the tobacco industry. On the one hand, our data
suggest the potential importance of snus in smoking cessation. Clearly, eliminating all forms
of tobacco use would have the greatest benefit on world health; however, many smokers are
unable to achieve lasting smoking cessation. From a harm reduction perspective, if snus
demonstrates: (a) superior efficacy as a smoking cessation aid in randomized clinical trials
(conducted by investigators independent of the tobacco industry and including fair
comparisons with the best smoking cessation regimens currently available) and (b) far lower
health consequences, then there may be a role for its use in public health interventions for
smoking cessation.
On the other hand, given the historical corruption of the scientific method by the tobacco
industry, we are aware that publishing data that support the use of one addictive tobacco
industry product (snus) to diminish the harm from another (cigarettes) is controversial and
opens the possibility for misuse of our findings. On balance, we have chosen to publish
these findings. We stress that substantial positive evidence should be required prior to any
incorporation of snus use into public health policy.
Summary
Our findings underscore the importance of snus use in relation to smoking cessation in
Sweden, and highlight the need to consider interactions between several variables and
smoking cessation. Snus use was a strong independent correlate of smoking cessation and,
as a part of a suggestive interaction, appeared to overshadow the independent effects of
FTND score, SES and BMI on smoking cessation. Future research should evaluate
prospectively the ramifications of snus use, with special emphasis on overall tobacco
cessation rates among snus users and the health effects of long-term snus use.
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